CM
CYTK icon

Crestline Management’s Cytokinetics CYTK Stock Holding History

Crestline Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-34,887
Closed -$2.91M – 179
2023
Q4 		$2.91M Buy
34,887
+14,887
+74% +$539K 0.25% 115
2023
Q3 		$589K Buy
+20,000
New +$666K 0.07% 136

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Crestline Management's CYTK Position: Q1 2024 in Review

Crestline Management sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 34,887 shares — an estimated $2.91M sold.

Crestline Management first reported a position in CYTK in Q3 2023 and held it in 2 quarters. The position peaked at $2.91M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Crestline Management reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Crestline Management sold 34,887 Cytokinetics shares in Q1 2024, an estimated $2.91M.
  • Crestline Management first reported a position in Cytokinetics in Q3 2023 and held it in 2 quarters.
  • Crestline Management's Cytokinetics position peaked at $2.91M in Q4 2023.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Crestline Management's 13F filing for Q1 2024, filed 14 May 2024.